Most Frequent Side Effects with Lurbinectedin and Atropine
Lurbinectedin ( Zepzelca) is FDA-approved for small cell lung cancer and commonly combined with atropine to reduce nausea and vomiting. In clinical trials, the most reported side effects (occurring in ≥20% of patients) include fatigue (55%), nausea (52%), decreased appetite (40%), musculoskeletal pain (33%), constipation (31%), dyspnea (25%), vomiting (23%), and diarrhea (22%).[1][2]
Key Side Effects from Lurbinectedin Plus Chemotherapy Combinations
Lurbinectedin is often paired with drugs like doxorubicin or irinotecan in trials for relapsed small cell lung cancer. Common overlapping effects include:
- Hematologic: Neutropenia (48%), anemia (41%), thrombocytopenia (23%).
- Gastrointestinal: Nausea (up to 70% with doxorubicin), vomiting (50%), constipation.
- General: Fatigue (60-70%), edema, pyrexia.
These intensify with chemo, leading to higher rates of grade 3-4 events like severe neutropenia (35-45%).[3][4]
How Long Do These Side Effects Last?
Most resolve within days to weeks post-infusion, but fatigue and neuropathy can persist 1-3 months. Myelosuppression peaks 7-14 days after dosing and recovers by cycle 2 with supportive care like G-CSF.[1][5]
Severe Risks in Combinations
Grade 3-4 events hit 69% of patients on lurbinectedin-atropine, including rhabdomyolysis (5%), pneumonitis (5%), and hepatotoxicity. Combinations raise infection risk from neutropenia (15%) and tumor lysis syndrome. Transaminase elevations occur in 10-15%.[2][6]
Patient Management and Differences from Monotherapy
Supportive measures cut nausea by 50% with atropine premedication. Compared to solo use, chemo combos double hematologic toxicity but improve response rates (35% ORR). Elderly patients (>65) see 10-20% higher fatigue and cytopenias.[1][4]
Clinical Trial Data on Incidence
| Combination | Fatigue | Nausea | Neutropenia (G3-4) | Source |
|-------------|---------|--------|---------------------|--------|
| Lurbinectedin + Atropine | 55% | 52% | 7% | [1] |
| + Doxorubicin | 68% | 70% | 45% | [3] |
| + Irinotecan | 62% | 65% | 38% | [4] |
[1]: Zepzelca Prescribing Information, FDA (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf)
[2]: Trigo et al., Lancet Oncol 2020 (IMforte trial)
[3]: Farago et al., J Clin Oncol 2023 (doxorubicin combo)
[4]: NCT02454972 trial results, ClinicalTrials.gov
[5]: Paz-Ares et al., Lancet Oncol 2021
[6]: DrugPatentWatch.com drug profile (no active lurbinectedin patents listed; https://www.drugpatentwatch.com/p/tradename/ZEPELCA)